Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis

Article Gastroenterology & Hepatology

FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort

Arka De et al.

Summary: The FAST score shows good discriminative ability for detecting NASH with significant fibrosis and inflammation in NAFLD patients. Cut-offs should be recalibrated based on disease prevalence.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Validation and Performance of FibroScan®-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease

Ana Carolina Cardoso et al.

Summary: The FAST score performs well in a Brazilian NAFLD population, even in patients with higher BMI when the XL probe is used. Thus, FAST can be utilized as a noninvasive screening tool to exclude the diagnosis of progressive NASH, reducing the need for unnecessary liver biopsies.

DIGESTIVE DISEASES AND SCIENCES (2022)

Add to Collection

Article Gastroenterology & Hepatology

MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis

Mazen Noureddin et al.

Summary: The study introduced a highly specific MRI-based score (MAST) to identify patients with Fibro-NASH, outperforming previous scores in non-invasively identifying patients at higher risk of liver disease progression.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery

Federica Tavaglione et al.

Summary: The study found that CAP measured using the XL probe is effective in grading liver steatosis in individuals with morbid obesity, and can assist in identifying suitable candidates for bariatric surgery and evaluating the impact of surgery on hepatic steatosis.

LIVER INTERNATIONAL (2022)

Add to Collection

Article Gastroenterology & Hepatology

Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis

Nobuharu Tamaki et al.

Summary: The study compared the diagnostic accuracy of MEFIB and FAST for detecting significant fibrosis in NAFLD patients, finding that MEFIB had higher accuracy and supporting the use of a two-step strategy for detecting significant fibrosis in NAFLD.

HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

Young-Sun Lee et al.

Summary: This study aimed to develop a scoring system for the diagnosis of nonalcoholic steatohepatitis (NASH) using multiparametric magnetic resonance (MR) and clinical indicators. The MRE-based NASH score showed satisfactory accuracy in diagnosing NASH in patients with nonalcoholic fatty liver disease (NAFLD).

HEPATOLOGY INTERNATIONAL (2022)

Add to Collection

Article Multidisciplinary Sciences

Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms

Tinsay A. Woreta et al.

Summary: The FAST (TM) score was validated for the diagnosis of at-risk NASH in a large, multi-racial population in North America, with diagnostic performance varying by subgroups defined by race and obesity. FAST (TM) performed better than other non-invasive algorithms for the diagnosis of at-risk NASH.

PLOS ONE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD

Beom Kyung Kim et al.

Summary: This study compared the diagnostic performance of three non-invasive testing models and found that the MEFIB model was the most effective in detecting significant fibrosis and at-risk non-alcoholic steatohepatitis (NASH).

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations

Zobair M. Younossi et al.

Summary: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are common liver diseases often associated with obesity, insulin resistance, and type 2 diabetes mellitus. The stage of fibrosis is the most important predictor of liver outcomes in NAFLD and NASH, underscoring the importance of early identification of patients with advanced fibrosis.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Zobair M. Younossi et al.

Summary: In patients with advanced NASH, baseline NIT scores and their changes over time are predictive factors for adverse clinical and PROs outcomes. Patients with higher NIT scores are more likely to experience disease progression and impaired PROs, while those with decreasing NIT scores may see improvements in PRO scores.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review

Zobair M. Younossi et al.

Summary: NAFLD is a leading cause of chronic liver disease globally, affecting over 25% of the population. Lifestyle modification for weight loss is the primary intervention for patients with NAFLD. Evidence-based interventions and best practice advice are provided for clinical management of NAFLD.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis

Jinho Jung et al.

Summary: The study demonstrated that the combination of MRE and FIB-4 showed high diagnostic accuracy in identifying patients with NAFLD who have stage 2 or higher fibrosis, making them suitable candidates for pharmacological therapy.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD

Vy H. Nguyen et al.

Summary: The study found that individuals meeting the criteria for MAFLD had more comorbidities and worse prognosis compared to those with NAFLD only. Non-NAFLD MAFLD participants had the highest cumulative incidence of all-cause mortality, followed by NAFLD-MAFLD and non-MAFLD NAFLD participants. The MAFLD criteria should be considered in the general population to identify high-risk groups for early interventions.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery

Abhinav Anand et al.

Summary: The FibroScan-aspartate aminotransferase (FAST) score demonstrated good discrimination for fibrotic non-alcoholic steatohepatitis and correlated well with histological response to interventions for NAFLD, despite a miscalibration resulting in overprediction.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Validation of the FibroScan-aspartate aminotransferase score by vibration-controlled transient and B-mode ultrasound elastography

Masashi Hirooka et al.

Summary: The FAST score using both VCTE and US-elastography showed similar diagnostic accuracy in identifying advanced non-alcoholic steatohepatitis. Cut-off values of <= 0.35 and >= 0.67 had high sensitivity and specificity for ruling out and diagnosing the condition, respectively. Overall, the FAST score demonstrated good reproducibility across different echo equipment and probes.

HEPATOLOGY RESEARCH (2021)

Add to Collection

Review Gastroenterology & Hepatology

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

Giovanni Targher et al.

Summary: NAFLD is not only a global public health issue but also proven to be a systemic disease, closely related to various extrahepatic complications. Addressing NAFLD requires establishing a multidisciplinary working group and framework to achieve comprehensive, person-centered care and management.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus

Daniel Ferguson et al.

Summary: NAFLD is the most prevalent liver disease worldwide, with no approved pharmacological therapies available. The spectrum of severity ranges from steatosis to NASH, which is linked to increased risks of liver cancer and cirrhosis. Therefore, a holistic approach and ongoing therapeutic options are necessary to address the global health burden of these diseases.

NATURE REVIEWS ENDOCRINOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Defining comprehensive models of care for NAFLD

Jeffrey Lazarus et al.

Summary: The paper discusses seven comprehensive models of care for patients with non-alcoholic fatty liver disease (NAFLD) and provides eight recommendations for policymakers and practitioners to address the increasing demand for good practice care for NAFLD patients.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism